Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Leukopenia and MET[original query] |
---|
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer 2013 Nov 109 (11): 2803-9. Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa |
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European journal of clinical pharmacology 2015 Sep . Diekstra Meta H M, Liu Xiaoyan, Swen Jesse J, Boven Epie, Castellano Daniel, Gelderblom Hans, Mathijssen Ron H J, Rodríguez-Antona Cristina, García-Donas Jesus, Rini Brian I, Guchelaar Henk-J |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: